Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkyl...

por Pujol, J-L, Carestia, Daurès, J-P
Publicado 2000

Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data

por Choma, D, Daurès, J-P, Quantin, X, Pujol, J L
Publicado 2001

Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis

por Boher, J-M, Pujol, J-L, Grenier, J, Daurès, J-P
Publicado 1999

Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer

por Pujol, P, Daurès, J-P, Brouillet, J-P, Maudelonde, T, Rochefort, H, Grenier, J
Publicado 1999

Economics of the clinical management of lung cancer in France: an analysis using a Markov model

por Chouaïd, C, Molinier, L, Combescure, C, Daurès, J P, Housset, B, Vergnenègre, A
Publicado 2004

A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index

por Colinet, B, Jacot, W, Bertrand, D, Lacombe, S, Bozonnat, M-C, Daurès, J-P, Pujol, J-L
Publicado 2005

CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients

por Pujol, J-L, Molinier, O, Ebert, W, Daurès, J-P, Barlesi, F, Buccheri, G, Paesmans, M, Quoix, E, Moro-Sibilot, D, Szturmowicz, M, Bréchot, J-M, Muley, T, Grenier, J
Publicado 2004